within Pharmacolibrary.Drugs.C_CardiovascularSystem.C10A_LipidModifyingAgentsPlain.C10AD04_AluminiumNicotinate;
model AluminiumNicotinate 
   extends Pharmacolibrary.Drugs.ATC.C.C10AD04;

  annotation(Documentation(
    info ="<html><body><p>Aluminium nicotinate is a coordination compound of aluminium and nicotinic acid (niacin). Historically, it has been investigated and used as a lipid-lowering agent in certain countries, particularly in Eastern Europe, but is not widely approved or used today in major regulatory regions such as the US or EU.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic (PK) data available for aluminium nicotinate in humans. Parameters below are estimated for a hypothetical healthy adult individual based on related compounds (e.g., niacin) and general PK principles for oral metal complexes.</p><h4>References</h4><ol><li><p>Makris, KC, et al., &amp; Sylvia, VL (2008). In vitro model improves the prediction of soil arsenic bioavailability: worst-case scenario. <i>Environmental science &amp; technology</i> 42(16) 6278â€“6284. DOI:<a href=&quot;https://doi.org/10.1021/es800476p&quot;>10.1021/es800476p</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18767699/&quot;>https://pubmed.ncbi.nlm.nih.gov/18767699</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end AluminiumNicotinate;
